Collaboration Revenue (Details Textual)					1 Months Ended	3 Months Ended
	Jul. 26, 2019 USD ($)	Jun. 18, 2019 USD ($) Target $ / shares shares	Jun. 17, 2019 $ / shares shares	Feb. 11, 2019	Oct. 31, 2017 USD ($)	Mar. 31, 2021 USD ($) VaccineDose shares	Dec. 31, 2020 USD ($) shares	Oct. 31, 2020 USD ($)	Jun. 16, 2019 Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						$ 29,249,000	$ 30,620,000
Purchase of common stock, shares | shares						26,319,000	26,192,000
Israeli Ministry of Health (“MOH”) [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received								$ 12,500,000
Number of reserved vaccine doses | VaccineDose						500,000
Maximum [Member] | Collaboration Partner CureVac Entered Into Co Development Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential target license term	8 years
Minimum [Member] | Collaboration Partner CureVac Entered Into Co Development Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential target license term	4 years
Research Collaboration And Exclusive License Agreement [Member] | Collaboration Partner Janssen [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received					$ 7,700,000
Research Collaboration And Exclusive License Agreement [Member] | Collaboration Partner Janssen [Member] | ASC 606 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation						$ 0
Deferred revenue						5,900,000	$ 5,900,000
Research Collaboration And Exclusive License Agreement [Member] | Collaboration Partner - Ultragenyx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received		$ 6,000,000.0				27,900,000
Revenue recognition potential milestone revenue recognized						$ 138,000,000.0
Option exercise fee received							500,000
Royalty payment term description						Ultragenyx will pay royalties as a single-digit percentage of net sales on a product-by-product and country-by-country basis during the applicable royalty term.
Number of targets | Target		12							10
Purchase of common stock, shares | shares		2,400,000
Purchase of additional shares of common stock | shares		600,000	600,000
Purchase of additional shares of common stock price per share | $ / shares		$ 16.0	$ 16.00
Consideration received		$ 30,000,000.0
Consideration received for common stock purchase		24,000,000.0
Transaction price		$ 14,400,000
Research Collaboration And Exclusive License Agreement [Member] | Collaboration Partner - Ultragenyx [Member] | ASC 606 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation						$ 0
Deferred revenue						$ 8,300,000	9,200,000
Revenue, practical expedient description						The Company recognizes the reimbursement of labor and expenses as costs are incurred and none of the development and commercialization milestones were included in the transaction price, as all milestone amounts were fully constrained.
Cumulative catch up adjustment						$ 1,100,000
Revenue recognition, reserve target exclusivity period						4 years
Research Collaboration And Exclusive License Agreement [Member] | Maximum [Member] | Collaboration Partner Janssen [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition potential milestone revenue recognized					$ 56,500,000
Research Collaboration And Exclusive License Agreement [Member] | Maximum [Member] | Collaboration Partner - Ultragenyx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise revenue range per target						$ 1,500,000
Lack of marketability discount restricted period		2 years
Research Collaboration And Exclusive License Agreement [Member] | Minimum [Member] | Collaboration Partner - Ultragenyx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise revenue range per target						$ 500,000
mRNA Technology [Member] | Collaboration Partner - CureVac [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payment term description						CureVac will pay royalties as a percentage of net sales on a product-by-product and country-by-country basis during the applicable royalty term in the low single-digit range
Development and option agreement date						2018-01
Expiration of initial term						8 years
Option to extend initial term on an annual basis						3 years
mRNA Technology [Member] | Collaboration Partner - CureVac [Member] | Rare Disease Targets [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition potential milestone revenue recognized						$ 14,000,000.0
mRNA Technology [Member] | Collaboration Partner - CureVac [Member] | Non-Rare Disease Targets [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition potential milestone revenue recognized						23,000,000.0
mRNA Technology [Member] | Collaboration Partner - CureVac [Member] | ASC 606 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation						0
Deferred revenue						$ 2,100,000	2,300,000
Revenue, practical expedient description						The Company recognizes the reimbursement of labor and expenses as costs are incurred and none of the development and commercialization milestones were included in the transaction price, as all milestone amounts were fully constrained.
Adjustments to transaction price						$ 0
Upfront fee received						$ 5,000,000.0
Contractual term						28 months
Cumulative catch up adjustment						$ 400,000
mRNA Technology [Member] | Collaboration Partner CureVac Entered Into Co Development Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement termination date				Feb. 11, 2019
Percentage of global rights reassumed				100.00%
Termination Agreement [Member] | Collaboration Partner CureVac Entered Into Co Development Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement settlement obligation one-time settled amount	$ 4,000,000.0
Other Collaboration Agreements [Member] | Takeda Pharmaceutical Company Limited [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						$ 300,000	$ 400,000